Congress Asset Management Co. Acquires 1,052,509 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Congress Asset Management increased its Halozyme stake by 85.6%, acquiring 1.05 million additional shares to own 2.28 million shares valued at approximately $251.9 million, or 2.01% of the company.
• Halozyme reported stronger-than-expected quarterly results, with EPS of $2.28 versus $1.79 expected and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analysts maintain a generally positive view, with nine Buy ratings and a consensus “Moderate Buy” rating, although the average price target of $91.20 is below the reported share price of $109.72. Meanwhile, insiders sold 87,775 shares worth $9.3 million over the past three months.

Congress Asset Management Co. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 85.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,281,615 shares of the biopharmaceutical company's stock after acquiring an additional 1,052,509 shares during the quarter. Halozyme Therapeutics comprises about 1.6% of Congress Asset Management Co.'s investment portfolio, making the stock its 7th largest holding. Congress Asset Management Co. owned approximately 2.01% of Halozyme Therapeutics worth $251,890,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of HALO. Twin Capital Management Inc. increased its holdings in shares of Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 161 shares during the period. First Citizens Bank & Trust Co. boosted its stake in shares of Halozyme Therapeutics by 2.0% in the first quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 175 shares during the period. Nations Financial Group Inc. IA ADV grew its position in Halozyme Therapeutics by 1.2% during the first quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company's stock worth $981,000 after buying an additional 183 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in Halozyme Therapeutics by 0.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,373 shares of the biopharmaceutical company's stock worth $1,640,000 after acquiring an additional 202 shares during the period. Finally, Tema ETFs LLC lifted its position in shares of Halozyme Therapeutics by 0.6% during the 2nd quarter. Tema ETFs LLC now owns 32,598 shares of the biopharmaceutical company's stock valued at $2,551,000 after acquiring an additional 210 shares during the period. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $1.41 on Tuesday, hitting $109.72. 1,774,255 shares of the company's stock were exchanged, compared to its average volume of 1,930,240. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $116.85. The stock has a market cap of $12.45 billion, a P/E ratio of 32.75, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. The company has a 50 day moving average of $104.03 and a 200 day moving average of $81.87.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business's revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on HALO shares. Citizens Jmp raised their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research report on Friday, August 7th. Weiss Ratings raised shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, August 31st. HC Wainwright reiterated a "buy" rating and set a $115.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, September 2nd. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, TD Cowen upped their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $91.20.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,775 shares of company stock worth $9,311,844 in the last three months. 2.50% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.